Wird geladen...
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma
Proteasome inhibition is an effective treatment for multiple myeloma (MM); however, targeting different components of the ubiquitin–proteasome system (UPS) remains elusive. Our RNA-interference studies identified proteasome-associated ubiquitin-receptor Rpn13 as a mediator of MM cell growth and surv...
Gespeichert in:
| Veröffentlicht in: | Leukemia |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6783320/ https://ncbi.nlm.nih.gov/pubmed/30962579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0467-z |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|